Brain injury in premature infants is the primary cause of cerebral palsy and cognitive dysfunction in preterm infants, posing a severe threat to their physical and mental health. However, its causes are complex, and as a link between the mother and the fetus, the placenta is closely related to the development of the fetal nervous system.
Some researchers claim that the occurrence of chorioamnionitis in the maternal placenta is one of the risk factors for BIPI (
18). Upon maternal placenta developing HCA, we found the incidence of BIPI to be 29.1%, which was 2.96 times higher than the incidence of brain injury in the HCA- group and was in agreement with the study of Guillen et al. (
19). Fukuda et al. (
20) observed that after the occurrence of placental HCA, reduced placental blood flow could cause a significant decrease in the fetal cerebral blood flow. As a result, the susceptibility of neurons to hypoxic injury increases, stimulating a vascular inflammatory cascade response, which in turn exacerbates the injury to the brain parenchyma (
21). Moreover, HCA can activate the microglia by causing fetal inflammatory response syndrome, leading to the production of a large number of inflammatory cytokines and injury to the central nerve cells, axonal degeneration, and destruction of the immature blood-brain barrier. The final consequence is BIPI. Meanwhile, inflammatory factors raise the activity of caspase and a large number of cytotoxic substances, such as excitatory amino acids, that cause brain cell apoptosis (
22). When HCA occurs in the placenta, BIPI may eventually occur in various ways. In this study, the incidence of BIPI was 30.3% in mothers who did not use AS before delivery, which was significantly higher than that observed in the AS+ group. This suggested that the prenatal use of steroid hormones could effectively prevent the occurrence of BIPI, which was consistent with other studies (
23). The PVL is a common type of BIPI. Some researchers believe that the application of AS can significantly reduce the time of mechanical ventilation and the incidence of PVL, while AS can act as a protective factor against PVL in premature infants (
24).
Many studies evaluate the correlation between AS and BIPI, and a line of evidence has confirmed that the prenatal use of AS can reduce BIPI occurrence. Consequently, the influence of placental inflammation on BIPI is included when studying the relationship between AS and BIPI. In this study, the subjects were divided into HCA+ AS+, HCA+ AS-, HCA- AS+, and HCA- AS- groups based on the results of the placental pathological examination and prenatal steroid hormone use. The incidence of brain injury in the HCA+ AS+, HCA+ AS-, and HCA- AS- groups was significantly higher than in the HCA- AS+ group. Compared to the HCA+ AS- group, the incidence of BIPI in the HCA- AS+ group was lower than in the HCA- AS- group, which indicated that the adequate use of AS before delivery could reduce the incidence of BIPI regardless of placenta inflammation. This may be related to the pharmacological action of AS, which can promote the maturation of fetal brain tissue (
25), stabilize cerebral capillaries and blood pressure hemodynamics (
26,
27), reduce basal metabolism, inhibit brain injury mediated by hypoperfusion (
28), inhibit toxic organic cytokines, and reduce nerve cell apoptosis (
29).
Intrauterine infection in preterm infants stimulates the production of inflammatory cells and secretion of large amounts of inflammatory cytokines, both of which directly or indirectly trigger ischemia and hypoxia in nerve cells, affecting the development of the nervous system in preterm infants (
29-
31). Procalcitonin is an inflammation-related factor synthesized rapidly and is free from the effects of hormones. When inflammation occurs, PCT levels are significantly elevated. However, after the inflammation is controlled, PCT levels decline rapidly, which can be used as an indicator to assess the inflammatory response (
32). Few relevant studies have been conducted at home and abroad to investigate the importance of using PCT as a monitoring indicator to predict the occurrence of BIPI with HCA and for early guidance in diagnosing and treating brain injury. In the present research, no statistical difference was observed in the WBC and CRP levels of different groups. However, PCT levels exhibited differences between the groups, where the HCA+ AS- group showed higher PCT levels than the HCA- AS- group. To evaluate the occurrence of BIPI with intrauterine infection, ROC curves were plotted, and it was found that the area under the ROC for PCT levels within 2 h was 0.731 postnatally. According to the Youden index, the critical value of PCT within 2 h was 2.213 ng/mL, while the sensitivity and specificity were 70.7% and 80.2%, respectively. In other words, when the PCT level was 2.213 ng/mL on admission, it showed a certain reference value for judging whether premature infants with intrauterine infection had a brain injury.
In summary, BIPI is associated with intrauterine infection in the mother and the lack of an entire course of steroid hormones before delivery. It is more likely to occur in the presence of both. Therefore, AS should be emphasized in clinical work, while routine placental pathology can be recommended for mothers at 28 - 30 weeks of gestational age to avoid a missed diagnosis of HCA, reducing the incidence of BIPI and improving the prognosis. The serum PCT levels after 2 h of birth can provide a laboratory basis for the early monitoring of BIPI. We found that a value of 2.213 ng/mL on admission bears a certain reference value for determining brain injury occurrence in preterm infants with intrauterine infection.